Intensity Therapeutics Announces 1-for-25 Reverse Stock Split

An announcement from Intensity Therapeutics, Inc. ( (INTS) ) is now available.

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company specializing in intratumoral cancer therapies built on its proprietary DfuseRx technology, is advancing its lead candidate INT230-6 through Phase 2 and Phase 3 trials in soft tissue sarcoma and breast cancer. The investigational therapy, which combines cisplatin, vinblastine sulfate and a diffusion enhancer to promote localized tumor killing and systemic immune engagement, has been studied in more than 200 patients and is designed for tumors that respond poorly to conventional immunotherapies.

On February 13, 2026, Intensity’s board implemented a 1-for-25 reverse stock split of its common stock, which will take legal effect at 4:01 p.m. Eastern Time on February 18, 2026, with post-split trading on the Nasdaq Capital Market starting February 19 under the unchanged ticker INTS and a new CUSIP. The move will shrink the company’s outstanding share count from about 63.3 million to roughly 2.5 million without changing authorized shares, adjust all equity-linked securities proportionally, and provide cash in lieu of fractional shares, as Intensity seeks to lift its share price and regain compliance with Nasdaq’s minimum bid requirements.

The most recent analyst rating on (INTS) stock is a Hold with a $0.34 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.

Spark’s Take on INTS Stock

According to Spark, TipRanks’ AI Analyst, INTS is a Neutral.

The score is primarily constrained by weak financial performance (no meaningful revenue, ongoing losses, and material cash burn indicating continued reliance on external funding). Technicals also weigh on the score with bearish trend signals (below short-term moving averages and negative MACD). Valuation is neutral-to-weak because a negative P/E limits comparability and there is no dividend yield support.

To see Spark’s full report on INTS stock, click here.

More about Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on developing novel intratumoral cancer therapies using proprietary non-covalent conjugation chemistry to deliver aqueous cytotoxic-containing formulations into tumors. Its lead candidate, INT230-6, combines cisplatin, vinblastine sulfate and a diffusion enhancer for direct tumor injection, and is being evaluated across multiple Phase 2 and Phase 3 trials in soft tissue sarcoma and breast cancer, targeting malignancies that are often unresponsive to conventional immunotherapy.

The company’s platform aims to saturate tumors’ dense, high-fat microenvironment, promoting rapid tumor killing and adaptive immune activation while maintaining a favorable safety profile. Intensity has completed two clinical studies with over 200 patients and is pursuing additional late-stage programs, positioning itself in the oncology space as a potential paradigm shifter toward turning certain deadly cancers into chronic, manageable diseases.

Average Trading Volume: 1,939,308

Technical Sentiment Signal: Sell

Current Market Cap: $22.47M

For detailed information about INTS stock, go to TipRanks’ Stock Analysis page.